OBJECTIVES: To examine rates of potentially inappropriate prescribing in a population dually eligible for Medicare and Medicaid during the period 1999 through 2004. METHODS: Descriptive analyses (population parameter assessments) were conducted on the 1999 through 2004 Medicaid fi les for elderly dually eligible enrollees. Inappropriate drugs independent of diagnosis as identifi ed by the 1997, beers drug list were analyzed. RESULTS: Proportionally, decreases in Beers drug use occurred in the initial year, 1999-2000; thereafter Beers drug use increased. The younger elderly (i.e., 65-74 years old) showed an increase in Beers drug use from 1999 to 2004 (20%) while older elderly (age 85 ) showed a decrease in use (11%). Hispanics had the greatest increase in use of Beers drugs (13%) during the study period followed by African-Americans (10%). Our results indicate that for central nervous system products prescribing patterns increased by 43.22% for the elderly dually-eligible population during this period of time, followed by neuromuscular prescriptions (31.92 percent) as compared to all Beers prescriptions dispensed. Within therapeutic category, we found that Beers drug use for neuromuscular drug products had the highest increase during the study period at 13.42% followed by central nervous system drugs at 4.57%. CONCLUSIONS: Our results underscore the need for medical professionals to make a conscious effort to familiarize themselves with Beers drugs so that when treating the elderly these risks can be reduced. We found that Beers drug use among the younger elderly is rising. We also found that Beers drug use is increasing among the Hispanic-American and African-American populations.
PHP30 A SYSTEMATIC LITERATURE REVIEW OF ELECTRONIC MONITORING DEVICES FOR MEASURING MEDICATION ADHERENCE
Shi L 1 , Koleva YN 1 , Chhabra P 1 , Walker PD 1 , Kalsekar A 2 , Pawaskar MD 3 1 Tulane University, New Orleans, LA, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA, 3 Eli Lilly and Company, Indianpolis, IN, USA OBJECTIVES: Self-reported questionnaires provide an easy way to measure adherence, however they can be subject to misrepresentation. This study reviewed electronic monitoring devices for measuring adherence to oral, inhaled, and injectable medications. METHODS: The literature search was performed from 1980-2008 using PubMed, PubMed In Process and Non-Indexed, OVID MEDLINE, PsycINFO (EBSCO), CINAHL (EBSCO), OVID HealthStar, EMBASE (Elsevier), and Cochrane Databases. The following search terms were used: patient compliance, medication adherence, treatment compliance, drug monitoring, drug therapy, electronic, digital, computer, monitor, monitoring, drug, drugs, pharmaceutical preparations, compliance, and medications. Two authors independently reviewed titles and abstracts, which were ranked by 3-point scoring (1 point for monitoring device, 1 point for adherence topic, and 1 point for medication) for relevance and publications were retrieved in full text for data extraction. Additionally, a search on the United States patents was performed for relevant information. RESULTS: From 1679 relevant citations, full-text review was conducted for 156 articles (scored 3 points), of which 123 studies (79%) used medication event management system (MEMS) caps. A total of 46 (30%) of all studies used electronic monitoring devices in clinical trial settings. Adherence was monitored in 105 (67%) studies, most frequently in HIV/AIDS (n 26), followed by hypertension (n 8), depression (n 7), diabetes (n 7), and asthma (n 6). Additionally, self-reported adherence was measured in 74 (47%) of studies and was found to correlate moderately well with electronic measures of adherence. No peer-reviewed studies using a monitoring device for injectable medications were found. Secondary search found 21 US patents relevant to medication monitoring; particularly three were designed for injectable regimens. CONCLUSIONS: MEMS remains a dominant device for measuring medication adherence. Commercialization of a device for measuring adherence with injectable and inhaled regimens may address the gap in health outcomes research for patients who have medical needs for these drugs.
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VARIABILITY OF FEES IN THE FIELD OF ULTRASOUND IN THE AUSTRIAN CONTRACTED PHYSICIANS' AND INSTITUTES' SECTOR
Weisser A, Wilbacher I, Scholler C, Endel G Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria OBJECTIVES: Contracts with contracted physicians or institutes that perform health care services can provide price advantages due to competition. The sickness funds of the Austrian Social Security signed a contract concerning ultrasound with physicians or institutes. Claims data, respectively rendered fees suggest a possible savings potential in the fee for service system without reducing the scope of the procedures or the frequencies. We analyzed the variety of fees in the fi eld of ultrasound including contracted physicians and institutes. This shows a variability among the total amount of reimbursement in the Austrian outpatient sector consisting of contracted physicians, institutes and outpatient clinics of hospitals and ambulatories. Approximately 30% of the Austrian outpatient sector cannot be displayed since no data is available. METHODS: Price differences for the same or similar procedures performed by different contracted physicians or institutes are evaluated and displayed. Different fi nancial impacts (e.g. focusing on average or lowest value) are simulated. Values were rounded to two decimal points, however, calculated by 15 decimal points. The fee equals the division of turnover/frequencies. RESULTS: A total of 78,131,670 ultrasound proce-dures were brought into account in the year 2006. Calculating all frequencies with the lowest paid fee (turnover/frequency) for each service would lead to a lower fi nancial effort of 40% compared to the current turnover. Calculating all frequencies with the highest fee for service would lead to a higher effort of 47% compared to the current turnover. CONCLUSIONS: A current savings potential of 47%, contrasting the current fee with the most expensive one, indicates a well established fee negotiation. However, a savings potential of 40% is worth being considered for further evaluation and, if necessary, the adjustment of fees is advisable.
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PHP32 EQUITY AND ACCESS TO GENERIC DRUGS: A COMPARISON OF GENERIC DRUG DISCOUNT PROGRAMS OFFERED BY CHAIN PHARMACIES IN THE UNITED STATES
Dwibedi N 1 , Patel H 1 , Sansgiry SS 2 1 University of Houston, HOUSTON, TX, USA, 2 University of Houston, Houston, TX, USA OBJECTIVES: Wal-Mart Stores (WMS) was the fi rst pharmacy to offer the Generic Drug Discount Program (GDDP) in 2006. The objective of this study was to compare GDDPs offered by large chain pharmacies in the United States. METHODS: A prospective cross-sectional fi eld study was conducted by obtaining data (March 2008 to November 2008) on GDDPs offered using a combination of telephone and face to face interview technique. Data obtained from the pharmacy included GDDPs offered, type of GDDP (patient cost for 30/90 day supply {DS}), number and type of drugs covered. Data coded in an excel sheet was analyzed by considering the WMS program as a reference to evaluate similarities/differences among GDDPs. Comparison were further performed by matching drugs covered in each GDDP with the top 100 generics (by units) consumed in the US in 2007. RESULTS: A total of 22 (of 37) pharmacies offered GDDPs. The patient sharing cost ranged from $3.99 to $9.99 for a 30DS and from $9.99 to $15.99 for a 90DS. Seven GDDPs (31.8%) were similar to WMS program with respect to number of generics covered (300-400), cost for 30DS ($4), and cost for 90 DS ($10). Four GDDPs (18.2%) were identifi ed as not at par with the WMS program, while 10 (45.4%) were identifi ed as superior. The superior GDDPs offered more drugs ( 400), while the inferior programs offered the same or less number of drugs at a higher cost ($9.99 for 30DS, and $12.99-$15.99 for 90DS). The GDDPs varied by the number of top 100 drugs covered with 72.7% covering more or same number of top 100 drugs as WMS. CONCLUSIONS: GDDPs were different across pharmacies in terms of number and type of generic medications covered, and cost for 30/90 day supply. Patients can save on generic drugs if they make the right choices. Children who did not get all the prescription medication needed in the past twelve months due to cost, health plan problem or lack of insurance were examined. Multivariate logistics models within the conceptual framework of Andersen's Behavioral Model were used to examine the predictors of UPMN due to cost, health plan problem and lack of insurance. RESULTS: According to NSCH, 35.39% children did not receive medications due to cost, 26.51 % due to health plan problem, and 40.73% due to lack of insurance. Multivariate logistic regression for UPMN due to cost revealed that children with attention defi cit hyperactive disorder (Odds Ratio (OR), 2.39) or asthma (OR, 3.15) were more likely to report UPMN due to cost and children having public insurance (OR, 0.26) or gained insurance (OR, 0.26) were less likely to report UPMN due to cost. Logistic regression model for UPMN due to health plan problem revealed that racial group other than whites and blacks (OR, 4.35), children with public insurance (OR, 11.98) and gained insurance (OR, 2.85) were more likely to report UPMN due to health plan problem. Lastly, children of 5-11 years (OR, 11.18) and 12-17 years (OR, 6.15) were more likely to report UPMN due to lack of insurance. CONCLUSIONS: Several predisposing, enabling and need factors are associated with UPMN due to cost, health plan problem and lack of insurance. Findings suggest that there is a need to focus on certain sociodemographic groups to improve access to prescription medication for children.
